begin privacyenhanced message proctype micclear originatorname webmasterwwwsecgov originatorkeyasymmetric mfgwcgyevqgbaqicafdsgawrwjawsnkkavtbzyzmragjlwykxmzvdtinen twsmvrzladbmyqaionwgsdwpoamdtdezxmmztbtwidaqab micinfo rsamdrsa vzcyjwwaexbhxpjsrhbgkydxeyrukqoustcvacqudedzoppjf qextzxcdztfcqzuyqfg txt 20100318 hdrsgml 20100318 20100318071342 accession number 000095012310025771 conformed submission type da public document count filed date 20100318 date change 20100318 subject company company data company conformed name global med technology inc central index key 0001009463 standard industrial classification servicesprepackaged software 7372 irs number 841116894 state incorporation fiscal year end 1231 filing value form type da sec act 1934 act sec file number 00554591 film number 10690193 business address street 12600 colfax street suite c city lakewood state zip 80215 business phone 3032382000 mail address street 12600 west colfax avenue street suite c city lakewood state zip 801253737 former company former conformed name global data technology inc date name change 19960808 filed by company data company conformed name global med technology inc central index key 0001009463 standard industrial classification servicesprepackaged software 7372 irs number 841116894 state incorporation fiscal year end 1231 filing value form type da business address street 12600 colfax street suite c city lakewood state zip 80215 business phone 3032382000 mail address street 12600 west colfax avenue street suite c city lakewood state zip 801253737 former company former conformed name global data technology inc date name change 19960808 da gscdzahtm da scdza united state security exchange commission washington dc 20549 schedule d solicitationrecommendation statement section d security exchange act 1934 amendment no global med technology inc name subject company global med technology inc name person filing statement common stock par value 001 per share series convertible preferred stock par value 001 per share title class security e cusip number class security michael ruxin chief executive officer global med technology inc 12600 west colfax suite c lakewood 80215 303 2382000 name address telephone number person authorized receive notice communication behalf person filing statement copy to clayton parker martin schrier kl gate llp 200 biscayne boulevard suite 3900 miami florida 33131 305 5393300 check box filing relates solely preliminary communication made commencement tender offer amendment no solicitationrecommendation statement schedule d amends supplement solicitationrecommendation statement schedule d filed global med technology inc colorado corporation global med security exchange commission the sec march 2010 a amended supplemented time time schedule d schedule d relates offer haemonetics corporation massachusetts corporation haemonetics wholly owned subsidiary atlas acquisition corp colorado corporation purchaser purchase outstanding share global meds common stock 001 par value per share the global med common stock outstanding share global meds series convertible preferred stock 001 par value per share the global med preferred stock upon term subject condition set forth haemonetics offer purchase dated february 19 2010 a amended supplemented time time offer purchase offer purchase attached exhibit aa schedule filed haemonetics sec february 19 2010 a amended supplemented time time schedule to term offer a defined below set forth offer purchase related letter transmittal global med common stock letter transmittal global med preferred stock each context requires letter transmittal together offer purchase offer capitalized term used otherwise defined herein shall respective meaning ascribed term schedule d item schedule d hereby amended supplemented replacing fourth paragraph subsection entitled background transaction following march 14 2008 chris lindop haemonetics chief financial officer vice president business development spoke telephone dr ruxin regarding potential relationship haemonetics company also discussed business entity development industry item schedule d hereby amended supplemented adding following end third bullet point subsection entitled reasons recommendation factor led special committees decision commence formal auction company included among thing i directors belief haemonetics strategic value gained combination global med compared potential suitor and thus would likely offer highest price ii concern company would strategic fit company iii concern companys management publicity likely resulting auction process could lead loss existing prospective customer andor key employee special committee also believed required notice customer would provide opportunity two company which company viewed two companys likely suitor submit proposal item schedule d hereby amended supplemented replacing first paragraph subsection entitled opinion st charles capital comparable public company analysis following comparable public company analysis st charles determined relevant compare global med directly comparable company market selecting directly comparable company st charles used following criterion i public company st charles professional judgment deemed highly comparable global med ii public company primarily engaged development sale blood management software closely related company engaged similar business iii public company traded major stock exchange criterion yielded two relevant public company haemonetics mediware st charles comparable company analysis table haemonetics mediware below st charles also determined relevant compare global med public company engaged development marketing sale software within healthcare industry selecting company st charles used following criterion i public company st charles professional judgment deemed comparable global med ii company primarily engaged healthcare information management software closely related business iii public company traded major stock exchange criterion yielded twelve relevant public company allscriptsmisys healthcare solution inc cerner corp computer program system inc eclipsys corporation isoft group limited logibec groupe informatique ltee mckesson 2 corporation medassets inc quadramed corp quality system inc starlims technology ltd system healthcare plc st charles comparable company analysis table twelve comparable company below addition st charles reviewed certain financial multiple based consideration paid offer merger 122 cash per share global med common stock enterprise value ebitda multiple software control transaction occurring last three year demonstrates market pay premium larger company such st charles utilized size discount compare larger public company size premium embedded implied enterprise value multiple reviewed included implied enterprise value company multiple companys latest twelve month revenue implied enterprise value company multiple companys latest twelve month ebitda september 30 2009 december 31 2009 st charles observed following multiple comparable public company directly comparable publiccompany multiple unadjusted multiple adjustment ltm e e ltm e e size control company name revenue revenue revenue ebitda ebitda ebitda discount premium haemonetics corp x x x x x x 334 261 mediware information system inc x x x x na na 261 average x x x x x x 167 261 adjusted multiple ltm e e ltm e e company name revenue revenue revenue ebitda ebitda ebitda haemonetics corp x x x x x x mediware information system inc x x x x na na average x x x x x x nm meaningful excludes revenue ebitda multiple excess x x respectively multiple negative na data available related public company comparable multiple unadjusted multiple adjustment ltm e e ltm e e size control company name revenue revenue revenue ebitda ebitda ebitda discount premium allscriptsmisys healthcare solution inc x x x nm x x 334 261 cerner corp x x x x x x 334 261 computer program system inc x x x x x x 211 261 eclipsys corporation x x x x x x 297 261 isoft group limited x na na x na na 297 261 logibec groupe informatique ltee x x x x x x 211 261 mckesson corporation x x x x x x 334 261 medassets inc x x x x x x 334 261 quadramed corp x na na x na na 211 261 10 quality system inc nm nm x x x x 334 261 11 starlims technology ltd x na na x na na 186 261 12 system healthcare plc x na na x na na 186 261 average x x x x x x 273 261 3 adjusted multiple ltm e e ltm e e company name revenue revenue revenue ebitda ebitda ebitda allscriptsmisys healthcare solution inc x x x nm x x cerner corp x x x x x x computer program system inc x x x x x x eclipsys corporation x x x x x x isoft group limited x na na x na na logibec groupe informatique ltee x x x x x x mckesson corporation x x x x x x medassets inc x x x x x x quadramed corp x na na x na na 10 quality system inc nm nm x x x x 11 starlims technology ltd x na na x na na 12 system healthcare plc x na na x na na average x x x x x x nm meaningful excludes revenue ebitda multiple excess x x respectively multiple negative na data available item schedule d hereby amended supplemented replacing first paragraph subsection entitled opinion st charles capital comparable transaction analysis following comparable transaction analysis st charles also reviewed acquisition transaction occurring since january 2007 involving company transaction that st charles professional judgment deemed comparable company target company selected transaction enterprise value 20 million 1414 million primarily engaged healthcare information management software industry transaction greater fifty percent target corporation acquired detailed term transaction publicly available including term pricing related transaction multiple st charles compared revenue ebitda multiple discussed multiple implied transaction deemed comparable merger size discount described above utilized larger transaction comparable transaction follows listed acquirer followed acquired company comparable transaction mm implied date target name buyer name enterprise value 06232009 eresearchtechnology inc electronic data capture business omnicomm system inc 20 05302009 etrials worldwide inc nkamerge eclinical inc merge healthcare incorporated 182 04222009 waban software inc phase forward inc 140 02232009 emageon inc amicas inc 255 01272009 visage imaging inc pro medicus ltd 30 4 implied date target name buyer name enterprise value 12162008 shared pet imaging llc alliance imaging inc nkaalliance healthcare service inc 452 09082008 pharsight corporation tripos international 410 06032008 vip inc general dynamic information technology inc 2232 05212008 medquist inc cbay inc 2869 04292008 accuro healthcare solution inc medassets inc 3525 04282008 compiq corporation affiliated computer service inc 261 04112008 trizetto group inc apax partner worldwide 14142 04072008 escription inc nuance communication inc 3630 03242008 phoenix data system inc bioimaging technology inc nkabioclinica inc 240 03172008 fast track system inc medidata solution inc 181 01082008 cm inc elekta 750 12312007 extended care information network inc allscripts healthcare solution inc 854 07222007 misys healthcare system inc computerized patient record business nkaquadramed cpr quadramed corp 330 04012007 quovadx inc nkahealthvision inc battery venture vii lp battery venture 822 03012007 dendrite international inc nkacegedim dendrite cegedim 6726 02162007 vantagemed corporation nightingale informatix corporation 115 item schedule d hereby amended supplemented adding following first sentence subsection entitled opinion st charles capital discounted cash flow analysis analysis discounted future cash flow st charles utilized widely accepted methodology discounting future projected cash flow estimated terminal value company combined represent estimate enterprise value business 5 item schedule d hereby amended supplemented adding following end subsection entitled opinion st charles capital discounted cash flow analysis discounted cash flow analysis performed st charles year 2010 2014 based estimate assumed future growth become increasingly speculative year beyond 2010 item schedule d hereby amended supplemented adding following paragraph end subsection entitled opinion st charles capital discounted cash flow analysis purpose discounting future free cash flow discounted cash flow analysis st charles used weighted average cost capital calculated set forth below weighted average cost capital cost equity 2003 equity total book capitalization 1 weighted cost equity we 107 cost debt 750 debt total book capitalization 1 weighted cost debt wd 35 wacc we wd 1422 1 september 30 2009 free cash flows represents total annual cash flow projected period may generated company tax operating capital expenditure item schedule d hereby amended supplemented adding following paragraph first paragraph subsection entitled st charles capital llc st charles never beneficially owned capital stock company addition business familial relationship exist st charles haemonetics purchaser global med dr ruxin mr marcinek m eames mr hunt mr gilmore mr willman item schedule d hereby amended supplemented adding following new paragraph fifth paragraph subsection entitled certain projected financial information projection april 2009 model prepared management company st charles participate preparation item schedule d hereby amended supplemented adding following end subheading entitled shareholder litigation march 2010 plaintiff corica plaintiff sham plaintiff obrien together consolidated plaintiffs sought consolidation cjc action sham action obrien action pending district court jefferson county golden colorado jointly filed three lawsuit amended 6 class action complaint defendant the amended complaint march 10 2010 court entered order consolidating three action consolidated action captioned carmelo corica joseph sham robert obrien michael ruxin al case no cv cv cv amended complaint aggregate restates allegation cause action cjc action sham action obrien action additionally consolidated plaintiff claim individual breached fiduciary duty global meds shareholder by among factor allegedly failing make material disclosure shareholder global meds schedule d concerning additional detail underlying fairness opinion st charles capital llc delivered global med certain background information further amended complaint alleges individual approved proposed transaction order provide liquidity global meds largest stockholder based allegation amended complaint seek judgment that among relief 1 provides injunctive relief preliminarily permanently enjoins offer 2 rescinds offer consummated 3 directs defendant account plaintiff member class damage profit special benefit allegedly obtained defendant result individuals alleged breach fiduciary duty 4 award consolidated plaintiff cost action including fee expense consolidated plaintiffs attorney expert believe amended complaint without merit march 10 2010 consolidated plaintiff filed motion seeking temporary restraining order enjoin offer consolidated plaintiff claim 1 without temporary restraining order likelihood irreparable harm consolidated plaintiff adequate remedy law 2 consolidated plaintffs substantial likelihood success merit 3 threatened injury consolidated plaintiff shareholder outweighs possible harm defendant 4 granting injunction disserve public interest believe motion temporary restraining order without merit march 17 2010 consolidated plaintiff defendant executed memorandum understanding settlement claim liability amended complaint the settlement memorandum connection settlement memorandum haemonetics agreed reduce amount termination fee 24 million global med agreed amend schedule d include supplemental disclosure without admission materiality supplemental disclosure those supplemental disclosure included amendment no schedule d party stipulated offer shall remain open additional five business day following date filing amendment no schedule d ie march 24 2010 party agreed confirmatory discovery shall conducted involving deposition representative st charles one member special committee party reached agreement concerning consolidated plaintiffs fee cost any defendant waived right challenge ground consolidated plaintiff file application fee cost court appropriate time settlement memorandum conditioned upon final approval court along customary provision approved court defendant released class member described amended complaint including consolidated plaintiff claim liability could alleged amended complaint including actual potential derivative individual class claim relating offer merger agreement schedule d schedule to disclosure matter relating arising offer merger event settlement finalized finally approved court plan vigorously defend consolidated plaintiffs claim item schedule d hereby amended supplemented adding following immediately subheading entitled forwardlooking statements k extension offer period march 18 2010 haemonetics issued press release announcing connection settlement memorandum purchaser extended offer 1200 midnight boston massachusetts time wednesday march 24 2010 unless extended offer previously scheduled expire 1200 midnight boston massachusetts time march th order reflect extension offer reference march 18 2010 date offer expires schedule d hereby replaced appropriate march 24 2010 7 item schedule d hereby amended supplemented changing subheading entitled k forwardlooking statements reflect following l forward looking statement item exhibit e amendment no agreement plan merger dated march 17 2010 global med technology inc haemonetics corporation atlas acquisition corp 8 signature due inquiry best knowledge belief certify information set forth statement true complete correct global med technology inc by s michael ruxin md name michael ruxin md title chief executive officer dated march 17 2010 9 exhibit index exhibit no description e amendment no agreement plan merger dated march 17 2010 global med technology inc haemonetics corporation atlas acquisition corp 10 exe gexvwewhtm exe exvwew exhibit e amendment no agreement plan merger amendment no agreement plan merger this amendment made entered march 17 2010 among haemonetics corporation massachusetts corporation parent atlas acquisition corp colorado corporation wholly owned subsidiary parent purchaser global med technology inc colorado corporation seller capitalized term used otherwise defined herein shall respective meaning ascribed agreement plan merger dated january 31 2010 among parent purchaser seller the merger agreement whereas party agreed amend merger agreement provide matter set forth herein whereas parent purchaser seller approved amendment therefore consideration mutual covenant herein contained valuable consideration receipt sufficiency hereby acknowledged party agree follows amendment section b section b merger agreement hereby amended replacing 2600000 2400000 entire agreement amendment merger agreement together exhibit annex schedule thereto document delivered party connection therewith confidentiality agreement constitute entire agreement supersede prior agreement understanding written oral among party hereto them respect subject matter hereof except amended amendment merger agreement remains full force effect governing law amendment shall governed construed accordance law commonwealth massachusetts without regard rule conflict law counterpart amendment may executed delivered including facsimile electronic transmission one counterpart shall deemed original and together shall constitute one instrument signature page follows witness whereof parent purchaser seller caused amendment executed sealed instrument duly authorized officer day year first written haemonetics corporation by s christopher lindop name christopher lindop title vice president chief financial officer atlas acquisition corp by s james oshaughnessy name james oshaughnessy title secretary global med technology inc by s michael ruxin md name michael ruxin md title chairman chief executive officer end privacyenhanced message